All News #Library
Rare Diseases
Mipletamig Shows 86% Clinical Benefit Rate With No CRS In AML
10 Mar 2026 //
PHARMIWEB
Aptevo Therapeutics Updates Program for Bispecific APVO711
08 May 2025 //
ACCESSWIRE
Aptevo Therapeutics $2.0M Direct Offering Priced Nasdaq Rules
21 Apr 2025 //
ACCESSWIRE

Market Place
Sourcing Support